Innova Captab Limited (NSE:INNOVACAP)

Market Cap	56.40B +22.8%
Revenue (ttm)	17.49B +34.5%
Net Income	1.54B +18.7%
EPS	26.92 +18.7%
Shares Out	57.22M
PE Ratio	36.62
Forward PE	27.27
Dividend	3.00 (0.30%)
Ex-Dividend Date	Jan 30, 2026

Volume	42,313
Open	1,002.00
Previous Close	996.50
Day's Range	952.20 - 1,002.00
52-Week Range	622.00 - 1,353.50
Beta	-0.03
Analysts	Buy
Price Target	1,116.00 (+13.24%)
Est. Earnings	Nov 6, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INNOVACAP

Financial Performance

In fiscal year 2026, Innova Captab's revenue was 16.30 billion, an increase of 31.06% compared to the previous year's 12.44 billion. Earnings were 1.41 billion, an increase of 9.87%.

Analyst Summary

According to 2 analysts, the average rating for INNOVACAP stock is "Buy." The 12-month stock price target is ₹1,116, which is an increase of 13.24% from the latest price.

Price Target

₹1,116

(13.24% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error